[{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"894cf8cb-0456-4299-b86d-2ea4d23be60a","acronym":"BMP-MDS","url":"https://clinicaltrials.gov/study/NCT06175923","created_at":"2023-12-20T06:19:40.931Z","updated_at":"2024-07-02T16:35:22.504Z","phase":"","brief_title":"Role of BMP Pathway in MDS Progression","source_id_and_acronym":"NCT06175923 - BMP-MDS","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" BMP2 • BMP4","pipe":"","alterations":" ","tags":["BMP2 • BMP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/27/2024","start_date":" 01/27/2024","primary_txt":" Primary completion: 01/27/2029","primary_completion_date":" 01/27/2029","study_txt":" Completion: 01/27/2034","study_completion_date":" 01/27/2034","last_update_posted":"2024-01-23"},{"id":"295272f8-aec7-4d92-83ea-e03a6cde0d00","acronym":"GFM-DAC-CMML","url":"https://clinicaltrials.gov/study/NCT02214407","created_at":"2022-04-24T08:56:51.932Z","updated_at":"2024-07-02T16:36:20.482Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","source_id_and_acronym":"NCT02214407 - GFM-DAC-CMML","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 10/14/2014","start_date":" 10/14/2014","primary_txt":" Primary completion: 07/05/2021","primary_completion_date":" 07/05/2021","study_txt":" Completion: 08/16/2021","study_completion_date":" 08/16/2021","last_update_posted":"2021-11-19"},{"id":"0d51a3ad-8be1-4d5c-b868-0529a1a899f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003736","created_at":"2021-01-17T22:52:53.866Z","updated_at":"2024-07-02T16:36:55.294Z","phase":"","brief_title":"MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer","source_id_and_acronym":"NCT00003736","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xcytrin (motexafin gadolinum)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/1999","start_date":" 06/01/1999","primary_txt":" Primary completion: 06/01/2002","primary_completion_date":" 06/01/2002","study_txt":" Completion: 06/01/2002","study_completion_date":" 06/01/2002","last_update_posted":"2019-09-24"},{"id":"34e5be18-1470-4c80-b04a-c3f608ab3951","acronym":"","url":"https://clinicaltrials.gov/study/NCT00637247","created_at":"2022-04-16T16:04:53.025Z","updated_at":"2024-07-02T16:37:01.477Z","phase":"Phase 2","brief_title":"A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer","source_id_and_acronym":"NCT00637247","lead_sponsor":"AmpliMed Corporation","biomarkers":" G6PD","pipe":"","alterations":" ","tags":["G6PD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Amplimexon (imexon)"],"overall_status":"Completed","enrollment":" Enrollment 142","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 06/01/2010","study_completion_date":" 06/01/2010","last_update_posted":"2019-03-20"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"},{"id":"04b616c9-6937-4ad6-ac25-c7e749052a9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00175838","created_at":"2022-04-24T08:54:14.281Z","updated_at":"2024-07-02T16:37:26.468Z","phase":"","brief_title":"Primary Thrombocythaemia 1 Trial","source_id_and_acronym":"NCT00175838","lead_sponsor":"University of Cambridge","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 1398","initiation":"Initiation: 07/01/1997","start_date":" 07/01/1997","primary_txt":" Primary completion: 11/01/2016","primary_completion_date":" 11/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-01-18"}]